Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01397734 · ClinicalTrials.gov registry record · Phase 1
Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)
A Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01397734: Clinical Trial Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
NCT01397734 is a Phase 1 study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01397734, a Phase 1 study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
In this research study, the investigators are looking to see whether the combination of arsenic trioxide with a tyrosine kinase inhibitor is safe, and what effects it has on chronic myelogenous leukemia.
Primary Outcome
To assess the safety and toxicity of arsenic in combination with TKI therapy for chronic phase CML patients
Interventions
- DRUG Arsenic trioxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2011-09 |
| Est. Completion | 2018-08-06 |
| Phase | Phase 1 |
Why NCT01397734 stopped before completion
NCT01397734 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which Arsenic trioxide is the first listed.
NCT01397734 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01397734 about?
NCT01397734 is a clinical study titled "Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)". In this research study, the investigators are looking to see whether the combination of arsenic trioxide with a tyrosine kinase inhibitor is safe, and what effects it has on chronic myelogenous leukemia.
What is the current status of trial NCT01397734?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2011-09. Estimated completion is 2018-08-06.
What interventions are being tested in trial NCT01397734?
The interventions under investigation include: Arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT01397734?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01397734's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia